Deals this week: Seres Therapeutics, Evotec AG, C4X Discovery

14th July 2016 (Last Updated July 14th, 2016 18:30)

Seres Therapeutics and Emulate have entered an agreement to advance the drug discovery for inflammatory bowel disease and other serious conditions.

Seres Therapeutics and Emulate have entered an agreement to advance the drug discovery for inflammatory bowel disease and other serious conditions.

According to the agreement, the two partners will jointly work to enhance Emulate’s intestine chip platform to identify a novel bacteria composition with therapeutic potential.

Evotec AG has entered a co-development agreement with Anitibiotic Research UK, to focus on the discovery of antibiotic resistance breakers (ARBs) to treat infections that are resistant to currently available antibiotics.

Pursuant to the agreement, the two partners will use the new antibiotic resistance breakers (ARBs) in conjunction with known antibiotics in order to reverse resistance and restore clinical utility of such antibiotics. It also enables Antibiotic Research to find new ways to extend life of its existing antibiotics.

"GW Pharma has announced an underwritten public offering of American Depository Shares (ADS)."

C4X Discovery Holdings plc has acquired drug discovery technologies such as chemoinformatics, computational chemistry and artificial intelligence from Molpex to optimise the drug development process.

The acquisition enables C4X Discovery to predict the quality of molecules such as absorption and solubility, which are required for human administration.

Crescita Therapeutics has divested its German-based manufacturing facility that produces an active ingredient in WF10 and Oxoferin and intellectual property of WF10 to Dr. Friedrich-Wilhelm Kuehne.

The transaction enables the company to reduce its cash burn.

GW Pharma has announced an underwritten public offering of American Depository Shares (ADS).

It has further announced that the underwriters will have a 30-day option to purchase the additional shares of ADS to roll out any over-allotments.

The company expects to raise gross proceeds of $150m from the offering.